BACKGROUND: Screening for colorectal cancer (CRC) with flexible sigmoidoscopy (FS) has been shown to reduce CRC mortality. The current study examined whether the observed mortality reduction was due primarily to the prevention of incident CRC via removal of adenomatous polyps or to the early detection of cancer and improved survival. METHODS: The Prostate, Lung, Colorectal, and Ovarian (PLCO) cancer screening trial randomized 154,900 men and women aged 55 to 74 years. Individuals underwent FS screening at baseline and at 3 or 5 years versus usual care. CRC-specific survival was analyzed using Kaplan-Meier curves and proportional hazards modeling. The authors estimated the percentage of CRC deaths averted by early detection versus primary prevention using a model that applied intervention arm survival rates to CRC cases in the usual-care arm and vice versa. RESULTS: A total of 1008 cases of CRC in the intervention arm and 1291 cases of CRC in the usual-care arm were observed. Through 13 years of follow-up, there was no significant difference noted between the trial arms with regard to CRC-specific survival for all CRC (68% in the intervention arm vs 65% in the usual-care arm; P 5.16) or proximal CRC (68% vs 62%, respectively; P 5 .11) cases; however, survival in distal CRC cases was found to be higher in the intervention arm compared with the usual-care arm (77% vs 66%; P<.0001). Within each arm, symptom-detected cases had significantly worse survival compared with screen-detected cases. Overall, approximately 29% to 35% of averted CRC deaths were estimated to be due to early detection and 65% to 71% were estimated to be due to primary prevention. CONCLUSIONS: CRC-specific survival was similar across arms in the PLCO trial, suggesting a limited role for early detection in preventing CRC deaths. Modeling suggested that approximately two-thirds of avoided deaths were due to primary prevention. Future CRC screening guidelines should emphasize primary prevention via the identification and removal of precursor lesions. Cancer 2017;123:4815-22.
INTRODUCTION
Colorectal cancer (CRC) is the fourth most common cancer and the second leading cause of cancer death in the United States. 1 Randomized controlled trials have shown that flexible sigmoidoscopy (FS) is effective in reducing CRC-specific incidence [2] [3] [4] [5] and mortality. 2, 4, 5 To the best of our knowledge, no studies to date have assessed whether the observed mortality reduction is due primarily to primary prevention via the removal of adenomatous polyps or due to the effects of early detection (ie, diagnosing CRC at an earlier stage at which mortality from the disease is less likely). This assessment is of importance because it will enhance the scientific understanding of how FS screening prevents CRC deaths and may further inform future CRC screening recommendations. Some guidelines have stressed favoring screening tests that enable primary prevention via the removal of adenomatous polyps. 6 The randomized Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial 2 evaluated screening versus usual care (control arm) for their effect on cancer-specific incidence and mortality in subjects in the United States. The colorectal component of PLCO included screening with FS, with a baseline screen and repeat screening performed at 3 or 5 years. 2 After a median follow-up of 11.9 years, screening with FS was found to reduce CRC incidence (21% reduction) and mortality (26% reduction) compared with usual care. 2 Two factors may have contributed toward the observed reduction in mortality: 1) the reduction in CRC incidence; and 2) the increased percentage of CRC cases detected early through screening in the intervention arm compared with the usual-care arm.
The objective of the current study was to assess whether the observed mortality reduction in PLCO was due primarily to early detection or prevention. A mortality effect due primarily to early detection should demonstrate a substantial survival advantage for CRC cases in the screened versus the control arm. Given the observed reduction in incidence, the absence of a substantial survival difference between trial arms would provide indirect evidence that the primary effect on mortality was due to prevention, because early detection can decrease mortality only by improving survival. To this end, we analyzed survival, as well as cancer stage and mode of detection, by trial arm. In addition, we developed a quantitative model that estimates the percentage of the mortality reduction that was due to primary prevention versus early detection, based on the observed incidence and survival in each arm.
MATERIALS AND METHODS

Study Design, Setting, and Participants
The PLCO study design has been described previously. 7 Briefly, PLCO was a large-scale, multicenter, randomized controlled trial designed to evaluate the effect of cancer screening for 4 types of cancer (ClinicalTrials.gov identifier NCT00002540). 7 Between 1993 and 2001, PLCO randomized 154,900 men and women to either an intervention or usual-care arm.
2 Eligible participants were aged 55 to 74 years at the time of enrollment and had no history of any of the trial cancers and were not currently undergoing treatment for cancer. Individuals in the intervention arm received screening for all sex-relevant PLCO cancers, including FS for CRC at baseline and at 3 or 5 years. 2 The median duration of follow-up was 11.9 years, with a maximum duration of 13 years in each arm. CRC incidence and all-cause mortality data were obtained from the participants' medical records released to PLCO. 2 Cause of death was adjudicated by a panel blinded to the treatment arm assignment. Participant demographics, screening history, and medical history were collected using a self-administered baseline questionnaire at the time of randomization. 2 The PLCO trial was approved by the institutional review board at each screening center. All participants provided informed consent.
Reason for the Detection of Cancer
On standardized forms, PLCO abstractors recorded the clinical assessment that led to the diagnosis of CRC for all participants using the categories "screen-detected," "symptomatic," and "other"; for "other," a verbatim text in the medical records was recorded. Because abstractors were instructed to select the "screen-detected" category only for PLCO protocol screens, and the "surveillance" category (for subjects followed for a history of adenoma) was used only on some versions of the abstracting forms, the verbatim text was reviewed by 2 investigators to identify cases not detected by PLCO screen (including those detected by fecal occult blood testing and screening colonoscopy, as well as FS) and cases detected because of surveillance. In addition, some cases originally classified as "other" were reassessed by the investigators to be symptomatic, screen-detected, or surveillance-detected, based on text review. Details are provided in Supporting Information Table 1 .
Study Outcomes, Measures, and Statistical Analysis
We estimated CRC-specific survival rates using KaplanMeier plots. Losses to follow-up and deaths due to other causes were treated as censored observations. 8 The logrank test was used to compare survival for different categories of cases, including trial arm, mode of detection, and anatomic location. In the analysis related to anatomic location of diagnosed CRC cases, colon anatomy was categorized as either proximal (cecum, ascending colon, hepatic flexure, and transverse colon) or distal (splenic flexure, descending colon, sigmoid colon, rectosigmoid, and rectum). Proportional hazards modeling also was used to examine the association between survival and study arm, the reason that led to the detection of the cancer, and anatomic location. These factors were examined in univariate as well as multivariate analyses; for the latter, the model controlled for age, race, and education. Reason for detection, anatomic location, and stage of disease were compared between the trial arms using the chi-square test.
We also attempted to estimate the percentage of CRC deaths avoided in the intervention arm that were due to either early detection or primary prevention via removal of adenomatous polyps. The underlying premise was to evaluate the expected number of CRC deaths if the observed cases in the usual-care arm had the survival of those in the intervention arm and similarly, the expected number of CRC deaths if the observed cases in the intervention arm had the survival of those in the usual-care arm. The former estimates the number of CRC deaths if only early detection (D ED ) was occurring and the latter the number of CRC deaths if only primary prevention (D PP ) was occurring. Denoting these as D ED and D PP , respectively, and the observed CRC deaths in the intervention and usual-care arms as D I and D UC , respectively, the relative numbers of deaths averted due to primary prevention and early detection can be estimated in 2 ways. To derive D ED and D PP , we calculated KaplanMeier CRC-specific survival curves for each trial arm. Then for each arm, the survival rate curve of the other trial arm was applied to its incident CRC cases to estimate expected deaths (see Supporting Information Method 1 for details).
RESULTS
Study Population
Of 154,900 individuals enrolled in PLCO, 77,445 and 77,455 individuals, respectively, were randomized to the intervention and usual-care arms. There were 1008 CRC cases in the intervention arm and 1291 cases in the usualcare arm. The baseline characteristics of the participants diagnosed with CRC were similar (Table 1) . Overall, the mean age at the time of diagnosis of CRC was 64 years, >50% of cases were male, approximately 85.30% were non-Hispanic white, and >60% had achieved a college education.
CRC-Specific Survival by Treatment Arm and Anatomic Location
Among those diagnosed with CRC, 253 subjects in the intervention arm and 351 subjects in the usual-care arm died of CRC. Cumulative CRC-specific survival curves by study arm are depicted in Figure 1A . The 13-year survival rates in the intervention and usual-care arms were 68% and 65%, respectively, and were not found to be significantly different (P 5 .16, log-rank test). Hazard ratios (HRs) for unadjusted and adjusted Cox regression models are summarized in Table 2 . After adjusting for race, age, and education, the HR for dying of CRC in the intervention arm compared with the usual-care arm was 0.87 (95% confidence interval [95% CI], 0.73-1.02).
Of 1008 diagnosed cases of CRC in the intervention arm, 478 were distal and 508 were proximal. Among 1291 CRC cases in the control arm, 669 were distal and 596 were proximal. The intervention arm had a significantly higher percentage of proximal CRC cases compared with the usual-care arm (51.5% vs 47.1%; P 5 .04, chi-square test) (see Supporting Information Table 2 ). CRC-specific survival curves by anatomic location of the tumor are depicted in Figures 1B and 1C . The 13-year survival rates for individuals diagnosed with distal CRC in the intervention and usual-care arms were 77% and 66%, respectively (Fig. 1B) . Survival curves were found to be significantly different by trial arm (P<.0001, log-rank test). However, no significant difference was observed between the survival rates in the intervention (68%) and usual-care (62%) arms in subjects diagnosed with proximal CRC (P 5 .16, log-rank test) after 13 years of followup (Fig. 1C) . In proportional hazards analyses, cases with distal CRC in the intervention arm were found to have a significantly lower risk of mortality compared with cases of distal CRC in the usual-care arm in both univariate (HR, 0.60; 95% CI, 0.46-0.77) and multivariate (HR, 0.62; 95% CI, 0.48-0.80) analyses (Table 2 ) adjusted for age, race, and education. No significant survival difference between trial arms was observed for proximal CRC cases (HR, 1.16; 95% CI, 0.92-1.45) ( Table 2) .
We also examined how CRC anatomic location and stage distribution varied by trial arm. Stage was categorized into either nonadvanced (TNM stages I and II) or advanced (stages III and IV). The overall percentage of advanced CRC cases was found to be similar between the 2 arms (40.0% in the intervention arm vs 42.7% in the usual care arm; P 5 .20, chi-square test) (see Supporting Information Table 3 ). For distal CRC, cases in the intervention arm were found to have a significantly lower percentage of advanced cancer compared with cases in the usual-care arm (30.7% vs 39.7%; P 5 .002, chi-square test) (see Supporting Information Table 4 ). However, no differences were observed for proximal CRC cases (P 5 .45, chi-square test). More details regarding stage distribution and anatomic location by trial arm are shown in Supporting Information Table 5 .
CRC-Specific Survival by Reason for Detection
Reason for the detection of cancer by treatment arm is shown in Table 3 . The intervention arm had a higher percentage of screen-detected cases (31.4% vs 11.0%; P<.0001, chi-square test) and a lower percentage of symptom-detected cases (57.5% vs 76.3%; P<.0001, chisquare test) compared with the usual-care arm. The percentage of surveillance-detected cases was small (4.0% in the intervention arm vs 2.2% in the control arm; P 5 .02, chi-square test). The CRC-specific survival curves for each treatment arm by reason for cancer detection are depicted in Figure  2 . HRs from unadjusted and adjusted Cox regression models for risk of death by reason for detection are presented in Table 2 . Survival curves were found to be similar regardless of treatment arm for each reason for detection; however, survival was found to be significantly different across reason-for-detection categories. Within the intervention arm, compared with the referent group of screendetected cancers, symptom-detected cases were found to have significantly worse survival in both univariate (HR, 4.0; 95% CI, 2.8-5.7) and multivariate (HR, 4.8; 95% CI, 2.8-5.8) analyses. Similar results were observed for the usual-care arm. There was no significant survival difference observed between surveillance-detected and screendetected cases. In the intervention arm, survival curves were not significantly different between cases not detected by PLCO screen and PLCO screen-detected cases (P 5 .36, log-rank test) (see Supporting Information Fig. 1 ).
Relative Effect of Early Detection Versus Primary Prevention on Mortality for CRC
The results of the model that attempted to partition CRC deaths attributable to primary prevention versus those attributable to early detection are shown in Figure 3 . The model estimated that D ED was 312 and D PP was 277. Subtracting D ED and D PP from the observed D UC (351 deaths) gave a total of 39 deaths averted due to early detection and 74 deaths averted due to primary prevention (Fig. 3A) . Alternatively, subtracting the observed D I (253 deaths) from D ED and D PP , respectively, gave an estimated 59 deaths averted due to primary prevention and 24 deaths averted due to early detection (Fig. 3B) . Therefore, the estimated percentages of deaths averted due to primary prevention are 65% (39/[39 1 74]) by the first method and 71% (59/[59 1 24]) by the second method, with the remaining percentages, 35% and 29%, estimated due to early detection. The total combined number of estimated deaths prevented, 113 and 84, respectively, by the 2 methods, are reasonably close to the observed number of 98 for CRC deaths prevented in the intervention arm (ie, 351-253).
DISCUSSION
Determining the relative effectiveness of primary prevention versus early detection is of importance in elucidating the primary mechanism through which CRC screening tests reduce CRC-specific mortality. Randomized controlled trials have shown that FS reduces CRC-specific incidence 2-5 and mortality. 2, 4, 5 In the PLCO trial, reductions in both mortality and incidence were demonstrated, with a mortality relative risk of 0.74 (95% CI, 0.63-0.87) and an incidence relative risk of 0.79 (95% CI, 0.72-0.85). 2 In the current study, we examined whether the mortality reduction in the intervention arm was due primarily to the early detection of CRC or to primary prevention via the removal of adenomatous polyps.
Among 1008 diagnosed CRC cases in the intervention arm, 31% were screen-detected, versus 11% of the 1291 CRC cases in the usual-care arm. The relatively low rate of screen-detected cancers in the intervention arm suggested a limited contribution of early detection toward reducing CRC-specific mortality. In addition, the percentage of CRC cases of an advanced stage of disease was found to be similar across arms, again suggesting a limited role for early detection. Furthermore, CRC-specific survival was relatively comparable across trial arms. In the intervention arm, the 5-year and 13-year CRC-specific survival rates were 75% and 68%, respectively, compared with the corresponding usual-care arm rates of 71% and 66%, respectively. For overall or proximal CRC cases, no significant differences were observed with regard to stage distribution or survival by trial arm. For cases of distal CRC, those in the intervention arm had significantly better survival than cases in the usual-care arm Blue indicates symptom-detected cases; black, screen-detected cases; green, surveillancedetected cases; red, other-detected cases. oth_C indicates other-detected usual-care (control) arm; oth_I, other-detected intervention arm; scrn_C, screen-detected usual-care (control) arm; scrn_I, screen-detected intervention arm; surv_C, surveillancedetected usual-care (control) arm; surv_I, surveillance-detected intervention arm; symp_C, symptom-detected usual-care (control) arm; symp_I, symptom-detected intervention arm.
(77% vs 66%), which is expected given that FS was the intervention and it examines the distal colon. However, despite the 10% improved survival rate for distal colon cancers in the intervention arm, this difference was not of sufficient magnitude to explain the overall 26% reduction in CRC-specific mortality. Thus, early detection does not appear to be the dominant contributor to mortality reduction, and therefore a significant role for primary prevention is suggested. We developed a simple, transparent model with which to derive quantitative estimates of the relative percentage of CRC deaths averted by early detection versus primary prevention. The results demonstrated that approximately 65% to 70% of the reduction was due to primary prevention and approximately 25% to 30% of the reduction was due to early detection. A limitation of the model is that it did not account for the effect of lead time or overdiagnosis on survival rates in the intervention arm. To the extent that lead time and/or overdiagnosis were occurring, this would artificially inflate the survival rates in the intervention arm and therefore overestimate the effect of early detection. However, only approximately 30% of cases in the intervention arm were screen-detected, and some cases in the usual-care arm (11%) also were screen-detected. Furthermore, lead time is estimated to be relatively short (1.6-4.0 years) for CRC, and overdiagnosis is not believed to be substantial. 9 Therefore, the quantitative effects of lead time and overdiagnosis were likely modest.
The model also assumes that the CRC cases prevented were similar with regard to prognosis and would have had survival similar to those that actually occurred. To the extent that the less aggressive cancers, with slower transition times from adenoma to CRC, were preferentially prevented, this would tend to inflate the estimation of deaths averted due to primary prevention. Although this may have occurred to some extent, an examination of tumor grade demonstrated a similar distribution across trial arms, with 20.0% of tumors in the intervention arm versus 20.5% of tumors in the usual-care arm being poorly differentiated or undifferentiated and 10.3% of tumors in the intervention arm versus 11.5% of tumors in the usual-care arm being well differentiated.
The current study has several other limitations. In the PLCO population, individuals of black race, Hispanic ethnicity, and lower socioeconomic status are underrepresented. In addition, for the analysis of verbatim text for the method of detection, there was some ambiguity in ascertaining the exact reason for cancer detection in some cases. The strengths of the current study include its large sample size and excellent long-term follow-up of participants.
The results of the current study found that CRCspecific survival was comparable across trial arms in the PLCO trial. There were no statistically significant survival differences observed between arms for overall CRC and for proximal CRC, and only a small survival benefit for distal CRC was noted in the intervention arm. The current study estimates indicated that approximately 65% to 70% of prevented CRC deaths were due to primary prevention, and only 30% to 35% were due to early detection. On the basis of these findings, we believe future recommendations for CRC screening should place a greater emphasis on the prevention of incident cases via the detection and removal of precursor lesions.
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